Decision Resources

Press Releases

  • Surveyed Rheumatologists Report That Otezla’s Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options

    July 2, 2015

    (July 1, 2015) - Burlington, Mass. Decision Resources Group finds that the three most frequently cited advantages of Otezla are its oral administration, alternative mechanism of action, and favorable safety profile, as reported by surveyed rheumatologists. Otezla was the first oral therapy specifically approved and launched for the treatment of active psoriatic arthritis in the United States. The current standard of care includes conventional oral treatments including disease-modifying antirheumatic drugs (DMARDs), such as methotrexate and sulfasalazine, and nonsteroidal anti-inflammatory drugs (NSAIDs). DMARDs and NSAIDs are expected to remain first-line treatment for peripheral arthritis and axial disease manifestations, respectively, due in large part to reimbursement requirements that restrict the use of more effective biologics to refractory patients. Otezla is generally perceived to have a level of efficacy in-between conventional DMARDs and biologics. Likewise, surveyed rheumatologists are divided as to whether they are more likely to initially prescribe Otezla to patients that have failed conventional DMARDs or patients that have failed biologics.

    Read More

  • Interventional Cardiology Device Markets in Europe, Japan, Latin America, and the U.S. each have Unique Characteristics that Contribute to Market Dynamics

    June 25, 2015

    (June 25, 2015) - Burlington, Mass. – Decision Resources Group finds that interventional cardiology (IC) device market dynamics depend heavily on geography. The European market will undergo growth due to continued adoption of premium-priced devices in Western Europe and strengthening economies in Eastern Europe. Similarly, the Latin American market will grow over the next 10 years as the economies in the region improve and governments invest in healthcare. Conversely, the IC device markets in two of the most developed countries, the United States and Japan, will contract over the next 10 years due to rapidly eroding device prices and relatively flat procedure growth.

    Read More

  • Asia Pacific Laparoscopic Device Market Strongly Impacted by Economic Expansion, Domestic Manufacturing, and Varying Device Preferences

    June 17, 2015

    June 17, 2015 - Burlington, Mass. – Decision Resources Group finds that the laparoscopic device market in the Asia Pacific region—including Australia, China, India, and South Korea—will grow at a much stronger rate compared to the market in the US and Europe through 2023. Growth will be primarily driven by expansion in China and India, which are underpenetrated. Economic expansion, government investment in health care, and improving training will lead to the growing adoption of laparoscopic procedures in both of these markets. By 2023, the Asia Pacific market will be approximately one-third of the size of the US market.

    Read More

  • Economic Headwinds and Increasing Government Oversight Create New Challenges for Competitors in the Latin American Medtech Market

    June 12, 2015

    June 12, 2015 - Burlington, Mass. – Decision Resources Group finds that economic instability and fluctuating currencies have created numerous hurdles for medical device manufacturers in Latin America. Brazil and Argentina in particular are facing difficult economies, and both countries have felt the impact of slowing economic growth in China, a key export partner. The combination of a strong USD and slumping Latin American currencies has also created challenges for distributors because devices are purchased from manufacturers in USD but reimbursed in local currency; as these currencies fall, the value of the reimbursement paid to distributors decreases in relation to the USD price. As a result, it is expensive and increasingly unprofitable to import devices into Latin American countries.

    Read More

  • The Cancer Immunotherapy Market Will Capture Major-Market Sales of Over $13 Billion In 2023 and Will be Dominated by Immune Checkpoint Inhibitors

    June 4, 2015

    June 04, 2015 - Burlington, Mass. – Decision Resources Group finds that the cancer immunotherapy market will experience an impressive 29% annual growth over the forecast period and will reach $13.3 billion in 2023 across the seven major markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan). Growth will be fuelled by successive label expansions of Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo (nivolumab) and Merck & Co.’s Keytruda (pembrolizumab) in new cancer indications and/or patient populations and by the expected launches of eight novel cancer immunotherapies, including four immune checkpoint inhibitors and four therapeutic vaccines. Immune checkpoint inhibitors (totaling seven agents) will claim a staggering 91% share of the cancer immunotherapy market in 2023.

    Read More

  • Decision Resources Group Sets Course in Helping Leading Healthcare Companies Understand the Convergence of Healthcare Markets

    May 14, 2015

    Acquires Healthcare Business Insights, a Leader in Provider-Focused Research and Services


    Burlington, MA – May 14, 2015 – Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd., announced today that it has acquired Healthcare Business Insights (HBI), a trusted provider of best practice research, training and services to more than 1,400 hospitals across the U.S. HBI’s member-centric Academies enable hospitals and health systems to share best practices and understand how best to address today’s most critical issues, with a focus on providing actionable solutions leading to significantly enhanced performance.
    Read More

  • Decision Resources Group Joins Veeva OpenKey Partner Program

    March 26, 2015

    DRG aligns with Veeva on new approach to customer data that’s open and easy

    Burlington, MA – March 26, 2015 –
    Decision Resources Group (DRG) today announced that it has joined the Veeva OpenKey Partner Program. Veeva OpenKey is a bold new approach to provide life sciences companies with customer data for healthcare professionals (HCP), healthcare organizations (HCO), and affiliations with consistent standards of quality and service.Read More

  • Decision Resources Group acquires Activate Networks

    March 2, 2015

    March 2, 2015--Burlington, Mass.  Decision Resources Group, a leading research and advisory company focused on high-value healthcare data, insights, and analytics, announced today that it acquired Activate Networks, a provider of network and relationship analysis. 
    Read More

  • Diane Corrado Appointed President, Life Sciences Product Solutions, for Decision Resources Group

    January 15, 2015

    January 15, 2015 - Burlington, Mass. – Decision Resources Group (DRG) today announced the promotion of Diane Corrado to the position of President, Life Sciences Product Solutions.  In this new role, Corrado will assume operational responsibility for DRG’s research, product and commercial teams.

    Read More

  • Mark Luck Olson Appointed President, Global Consulting Services, for Decision Resources Group

    January 14, 2015

    January 14, 2015 - Burlington, Mass. – Decision Resources Group (DRG), one of the world’s leading firms focusing on healthcare insights, data and analytics, and services, today announced the promotion of Mark Luck Olson to the position of President, Global Consulting Services.  In this role, Mr. Olson will continue to lead DRG’s global portfolio of consulting and professional services businesses.

    Read More

  • Industry-Leading Speakers Present Next Month at Managed Care Account Management Training in San Francisco

    October 23, 2014

    Comprehensive, Hands-On Training Will Give Account Managers Knowledge, Techniques and Confidence to Successfully Work with Their Managed Care AccountsRead More

  • Decision Resources Group Announces Its Spring Managed Markets Summit to be Held in New Orleans in March, 2015

    October 15, 2014

    Three-Day Conference Will Educate Pharmaceutical and Biotech Executives on the Current Trends, Issues and Challenges Facing the U.S. Managed Care IndustryRead More

  • Decision Resources Group Announces Its Managed Care Account Management Training Seminar to be Held Next Month in San Francisco

    October 7, 2014

    Comprehensive, Hands-On Training Will Give Account Managers Knowledge, Techniques and Confidence to Successfully Work with Their Managed Care AccountsRead More

  • ACOs Drive Up Generic Drug Prescriptions

    June 4, 2014

    The emphasis on drug costs is changing the way doctors in accountable care organizations (ACOs) prescribe, threatening the bottom line for branded therapies and the pharmaceutical industry.Read More

  • Decision Resources Group Announces Partnership with Saama Technologies

    June 4, 2014

    Pairs Best-in-Class Market Access Analytics and Data Integration Expertise with Best-in-Class Enterprise Analytics Solution Development and Implementation
    Read More

View All